Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential

Alessandro RizzoStruttura Semplice Dipartimentale Di Oncologia Medica per La Presa in Carico Globale Del Paziente Oncologico “Don Tonino Bello,” I.R.C.C.S, Istituto Tumori “Giovanni Paolo Ii”, Bari, ItalyCorrespondence[email protected]
View further author information

Antonio CusmaiStruttura Semplice Dipartimentale Di Oncologia Medica per La Presa in Carico Globale Del Paziente Oncologico “Don Tonino Bello,” I.R.C.C.S, Istituto Tumori “Giovanni Paolo Ii”, Bari, ItalyView further author information

Silvana AcquafreddaStruttura Semplice Dipartimentale Di Oncologia Medica per La Presa in Carico Globale Del Paziente Oncologico “Don Tonino Bello,” I.R.C.C.S, Istituto Tumori “Giovanni Paolo Ii”, Bari, ItalyView further author information

Lucia RinaldiStruttura Semplice Dipartimentale Di Oncologia Medica per La Presa in Carico Globale Del Paziente Oncologico “Don Tonino Bello,” I.R.C.C.S, Istituto Tumori “Giovanni Paolo Ii”, Bari, ItalyView further author information

Gennaro PalmiottiStruttura Semplice Dipartimentale Di Oncologia Medica per La Presa in Carico Globale Del Paziente Oncologico “Don Tonino Bello,” I.R.C.C.S, Istituto Tumori “Giovanni Paolo Ii”, Bari, ItalyView further author information

Click to increase image sizeClick to decrease image size

Declaration of interests

The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Disclosure statement

Peer reviewers on this manuscript have no relevant financial relationships or otherwise to disclose.

Additional information

Funding

This research received no financial support.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential

Information for

Open access

Opportunities

Help and information

Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential

Declaration of interests

Disclosure statement

Additional information

Funding

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature